“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial
December 15, 2023
NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate